Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States-Reference-Cited by-同舟云学术

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Published:2023-09 Issue: Volume:146 Page:155642
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Golabi Pegah,Paik James M.,Kumar Ameeta,Al Shabeeb Reem,Eberly Kathrine E.,Cusi Kenneth,GunduRao Nagashree,Younossi Zobair M.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference60 articles.

1. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review;Younossi;Hepatology,2023

2. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world;Henry;Aliment Pharmacol Ther,2022

3. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: data from the United States scientific registry of transplant recipients;Stepanova;Hepatol Commun,2022

4. Nonalcoholic steatohepatitis: global impact and clinical consequences;Kabarra;Endocr Connect,2021

5. Nonalcoholic fatty liver disease: review of management for primary care providers;Basu;Mayo Clin Proc,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups;Nutrition, Metabolism and Cardiovascular Diseases;2024-09

2. Association of fatty liver index with sudden cardiac arrest in young adults;Metabolism;2024-09

3. Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD;Cell Reports Medicine;2024-09

4. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

5. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis;Clinical Gastroenterology and Hepatology;2024-08